Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Summary

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Timeline

Start

2019-12-30

Primary completion

2026-08-31

Completion

2026-08-31

Publications

• Augustin M, Tauber M, Sidbury R, Silverberg JI, Papp KA, Thaci D, De Bruin-Weller MS, Reich A, Peris K, Barber K, Galus R, Kaszuba A, Zirwas M, Nahm WK, Trullenque G, Maintz L, Alpizar S, Son SW, Laquer V, Gold LS, Cheong SY, Ryzhkova A, Drahos A, Ulianov L, Piketty C. Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study. J Eur Acad Dermatol Venereol. 2026 May;40(5):841-855. doi: 10.1111/jdv.70080. Epub 2025 Oct 13.
• Brunner PM. A novel treatment approach for atopic dermatitis. Lancet. 2024 Aug 3;404(10451):407-409. doi: 10.1016/S0140-6736(24)01488-0. Epub 2024 Jul 25. No abstract available.

Drugs

Indications